Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Sort by: Newest first Oldest first A-Z Z-A

  • RPS Wales seeks Welsh members' views on pharmacy in palliative and end-of-life care

    The Royal Pharmaceutical Society (RPS) in Wales is conducting a survey of Welsh pharmacists’ experiences with palliative and end-of-life care. The survey also provides space to discuss current barriers to pharmacists’ involvement in such care, and to identify the tools, education or training that would help them to provide better care.

  • Side effect of Gilenya Subscription

    Progressive multifocal leukoencephalopathy has been added as an adverse event of unknown frequency to the summary of product characteristics for Gilenya (fingolimod; Novartis).

  • Side effects of Zytiga Subscription

    Increased alanine aminotransferase and increased aspartate aminotransferase are now listed as common adverse reactions in the summary of product characteristics for Zytiga (abiraterone; Janssen-Cilag). Hepatitis fulminant and acute hepatic failure have been added as rare adverse reactions.

  • NICE does not recommend ibrutinib Subscription

    The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend ibrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia. A consultation on the guidance will be available on the NICE website until 23 March 2016.

  • February 2016: SMC decisions Subscription

    The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter).  Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.

  • New indication for Inegy Subscription

    Inegy (simvastin, ezetimibe; Merck Sharp & Dohme) is now indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome, either previously treated with a statin or not. Further changes to the summary of product characteristics reflect this addition.

  • Consultation on new products for specialised services Subscription

    NHS England has launched a public consultation on a proposed number of new products for specialised services, including fampridine for multiple sclerosis in adult patients and ziconotide for chronic refractory cancer pain. The consultation is available from the NHS England website until 27 March 2016.

  • Maxolon recall Subscription

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specific batches of Maxolon (metoclopramidehydrochloride) solution for injection 5mg/ml, 2ml ampoules. Further details are available from the MHRA website.

  • CPPE Prescriber's guide Subscription

    The Centre for Pharmacy Postgraduate Education (CPPE) has launched a ‘prescriber’s guide’ for pharmacist prescribers to update their knowledge, develop their skills and gather evidence of their competence to prescribe. The guide is available from the CPPE website.

  • NICE recommends ezetimibe Subscription

    The National Institute for Health and Care Excellence (NICE) has published final guidance that recommends ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. The guidance is available from the NICE website.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.